Overview

Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures

Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This study is designed to provide short term efficacy and safety data of TRI476 in children with inadequately-controlled partial seizures. Patients will be randomized into either drug treatment or placebo group at 1:1 ratio, and receive their respective treatment for 8 weeks. The purpose of study is to confirm that TRI476 as adjunctive therapy is effective and safe.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Carbamazepine
Oxcarbazepine